Expert: Biogen Is Closing In On The 'Holy Grail' For Biotech Stocks

In this week's episode, Estimize is joined by Joe McCann, a former biotech analyst at CR Intrinsic and the CEO of Slingshot Insights.

In the episode, Joe discusses Biogen Inc BIIB new drug, which could be the holy grail for biotech stocks. Leigh and Joe also chat about a hedge fund that seeks to make drug prices cheaper, and wrap things up with a complete earnings overview for the biotech sector.